Tenemos algunos problemas en este momento. Los datos de mercado de esta página no están disponibles actualmente. Te pedimos un poco de paciencia, mientras tratamos de resolver el problema y restauramos tus listas personalizadas.

U.S. markets close in 4 hours 25 minutes
  • GlobeNewswire

    Infertility Drugs & Devices market is projected to grow at a CAGR of 6.2% by 2034: Visiongain

    Visiongain has published a new report entitled Infertility Drugs & Devices Market Report 2024-2034: Forecasts by Product (Drugs, Equipment, Media & Consumables, Accessories), by Procedure (Assisted Reproductive Technology, Artificial Insemination, Fertility Surgeries, Other), by Patient (Female, Male), by End-use (Fertility Centers, Hospitals & Surgical Clinics, Cryobanks, Research Institutes) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies. The Infertility D

  • GlobeNewswire

    Ceftriaxone Industry Research 2024: Effective Treatment of Multi-Drug Resistant Infections Bolsters Growth - Global Forecasts to 2032

    Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Global Ceftriaxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031" report has been added to ResearchAndMarkets.com's offering.The 'ceftriaxone market' is expected to grow at a CAGR of 3.1% during the forecast period of 2024 to 2032, driven by its efficacy in treating multi-drug resistant infections, the rising incidence of bacterial infections, and the

  • GlobeNewswire

    Vaisala Corporation: Share Repurchase 28.6.2024

    VAISALA CORPORATIONSTOCK EXCHANGE RELEASE 28.6.2024 Vaisala Corporation: Share Repurchase 28.6.2024 In the Helsinki Stock Exchange Trade date28.6.2024 Bourse tradeBuy ShareVAIAS Amount594SharesAverage price/ share39.9753EURTotal cost23,745.33EUR Vaisala Corporation now holds a total of 142 126 sharesincluding the shares repurchased on 28.6.2024 On behalf of Vaisala Corporation Nordea Bank Oyj Janne SarvikiviSami Huttunen Additional information Paula Liimatta tel +358 9 8949 2020, ir@vaisala.com

  • Business Wire

    New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

    TEL AVIV, Israel, June 28, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some reimbursement authorities after one year of continuous use.

  • CNW Group

    Media Advisory - Minister Petitpas Taylor to participate in commemorative events honouring the unknown Newfoundland First World War soldier

    The Honourable Ginette Petitpas Taylor, Minister of Veterans Affairs and Associate Minister of National Defence, will participate in commemorative events and activities alongside the official Government of Canada delegation as part of their activities to commemorate and honour the unknown Newfoundland First World War soldier.

  • GlobeNewswire

    International Petroleum Corporation Announces Results of Normal Course Issuer Bid and Updated Share Capital

    TORONTO, June 28, 2024 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 109,280 IPC common shares (ISIN: CA46016U1084) during the period of June 24 to 28, 2024 under IPC’s normal course issuer bid / share repurchase program (NCIB). IPC’s NCIB, announced on December 1, 2023, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission De

  • GlobeNewswire

    Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

    NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki. DNTH103 is an investigational classical pathway inhibitor that is uniquel

  • PR Newswire

    Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients

    Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the MG-ADL score from baseline over 24 weeks. These data are included in a presentation and are among eight abstracts that Johnson & Johnson will present at the European Academ

  • GlobeNewswire

    FirstBank Announces New Chief Risk Officer and Several Other Leadership Promotions

    Bank appoints Jennifer Payne as Chief Risk Officer and promotes several others across retail, credit, security and IT departments Jennifer Payne, CRO Jennifer has been with the bank for 23 years, and has worked in various leadership roles across the company, including President of Compliance and, most recently, President of Loan Servicing before she was appointed CRO. LAKEWOOD, Colo., June 28, 2024 (GLOBE NEWSWIRE) -- FirstBank, one of the nation’s largest privately held banks with a focus on “b

  • Simply Wall St.

    XOMA Corporation's (NASDAQ:XOMA) institutional investors lost 11% last week but have benefitted from longer-term gains

    Key Insights Given the large stake in the stock by institutions, XOMA's stock price might be vulnerable to their...